These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25109614)

  • 1. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.
    Lugaresi A; Rottoli MR; Patti F
    Expert Rev Neurother; 2014 Sep; 14(9):1029-42. PubMed ID: 25109614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East.
    Deleu D; Alsharoqi I; Al Jumah MA; Al Tahan AR; Bohlega S; Dahdaleh M; Inshasi J; Khalifa A; Szólics M; Yamout BI
    Int J Neurosci; 2011 Apr; 121(4):171-5. PubMed ID: 21329472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving adherence to injectable disease-modifying drugs in multiple sclerosis.
    Bayas A
    Expert Opin Drug Deliv; 2013 Mar; 10(3):285-7. PubMed ID: 23339371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study.
    Pozzilli C; Schweikert B; Ecari U; Oentrich W;
    J Neurol Sci; 2011 Aug; 307(1-2):120-6. PubMed ID: 21636099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.
    Stuart WH
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S19-25. PubMed ID: 15253686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group.
    Yamout BI; Dahdaleh M; Al Jumah MA; Al-Shammri S; Al Sharoqi I; Al-Tahan AR; Bohlega S; Deleu D; Inshasi J; Khalifa A; Szólics M
    Int J Neurosci; 2010 Apr; 120(4):273-9. PubMed ID: 20374075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis.
    Ožura A; Kovač L; Sega S
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S6-11. PubMed ID: 24321157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new electronic device for subcutaneous injection of IFN-β-1a.
    Exell S; Verdun E; Driebergen R
    Expert Rev Med Devices; 2011 Sep; 8(5):543-53. PubMed ID: 21728909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
    Lugaresi A
    Expert Opin Drug Deliv; 2013 Feb; 10(2):273-83. PubMed ID: 23252744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Lugaresi A
    Expert Opin Drug Deliv; 2009 Sep; 6(9):995-1002. PubMed ID: 19637982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Disease-modifying treatment of MS--progress with complications].
    Fagius J
    Lakartidningen; 2003 Mar; 100(13):1164, 1167-8. PubMed ID: 12705166
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
    Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
    Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
    Kleinman NL; Beren IA; Rajagopalan K; Brook RA
    J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-modifying drugs in multiple sclerosis.
    Keenan E; Porter B
    Nurs Stand; 2003 Aug 27-Sep 2; 17(50):39-45. PubMed ID: 14521125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E
    Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].
    Arroyo E; Grau C; Ramo C; Parra J; Sánchez-Soliño O;
    Neurologia; 2010 Sep; 25(7):435-42. PubMed ID: 20964990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach.
    Denis L; Namey M; Costello K; Frenette J; Gagnon N; Harris C; Lowden D; McEwan L; Morrison W; Poirier J
    J Neurosci Nurs; 2004 Feb; 36(1):10-22. PubMed ID: 14998102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy].
    Popova EV; Novikova KV; Khachanova NV; Konovalova OE; Kozhieva MK; Davydovskaya MV; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10. Vyp. 2):48-52. PubMed ID: 29359733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.